A Randomized-Controlled Trial Targeting Cognition in Early Alzheimer’s Disease by Improving Sleep with Trazodone (REST)
Journal of Alzheimer's Disease · 2024
DOI: 10.3233/jad-230635 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Alzheimer's Disease, 2024. Verfasst von Estelle Eyob und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Trazodone, Alzheimer Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a leading cause of mortality and morbidity among aging populations worldwide. Despite arduous research efforts, treatment options for this devastating neurodegenerative disease are limited. Sleep disturbances, through their link to changes in neural excitability and impaired clearance of interstitial abnormal protein aggregates, are a key risk factor for the development of AD. Research also suggests that the neuroprotective effects of sleep are particularly active during slow wave sleep. Given the strong link between sleep disturbance and AD, targeting sleep in the prodromal stages of AD, such as in mild cognitive impairment (MCI), represents a promising avenue for slowing the onset of AD-related cognitive decline. In efforts to improve sleep in older individuals, several pharmacologic approaches have been employed, but many pose safety risks, concern for worsening cognitive function, and fail to effectively target slow wave sleep. Trazodone, a safe and widely used drug in the older adult population, has shown promise in inducing slow wave sleep in older adults, but requires more rigorous research to understand its effects on sleep and cognition in the prodromal stages of AD. In this review, we present the rationale and study design for our randomized, double-bind, placebo-controlled, crossover trial (NCT05282550) investigating the effects of trazodone on sleep and cognition in 100 older adults with amnestic MCI and sleep complaints.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Förderung
- NIA NIH HHS
Zitieren
APA
Eyob, E., Shaw, J. S., Bakker, A., Munro, C., Spira, A., Wu, M., Rabinowitz, J. A., Peters, M., Wanigatunga, S., Zipunnikov, V., Thompson, R., Burhanullah, M. H., Leoutsakos, J. M., Rosenberg, P., & Greenberg, B. (2024). A Randomized-Controlled Trial Targeting Cognition in Early Alzheimer’s Disease by Improving Sleep with Trazodone (REST). Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-230635
Vancouver
Eyob E, Shaw JS, Bakker A, Munro C, Spira A, Wu M, et al. A Randomized-Controlled Trial Targeting Cognition in Early Alzheimer’s Disease by Improving Sleep with Trazodone (REST). Journal of Alzheimer's Disease. 2024. doi:10.3233/jad-230635
BibTeX
@article{Eyob2024,
author = {Eyob, Estelle and Shaw, Jacob S and Bakker, Arnold and Munro, Cynthia and Spira, Adam and Wu, Mark and Rabinowitz, Jill A and Peters, Matthew and Wanigatunga, Sarah and Zipunnikov, Vadim and Thompson, Richard and Burhanullah, M Haroon and Leoutsakos, Jeannie-Marie and Rosenberg, Paul and Greenberg, Barry},
title = {A Randomized-Controlled Trial Targeting Cognition in Early Alzheimer’s Disease by Improving Sleep with Trazodone (REST)},
journal = {Journal of Alzheimer's Disease},
year = {2024},
doi = {10.3233/jad-230635}
}
EUVIMED